ЖурналыПодпискаАрхивКнигиПроектыО насРекламаДоставка/ОплатаКонтакты
+7 (495) 482-43-29
  • Главная
  • / Журналы
  • / Вернуться в журнал
  • / Содержание номера
  • / Статья
Что не так?

Что не так?

Авторы:
Никита Владимирович Соловей,
Юлия Алексеевна Комарова

Журнал: Non nocere. Новый терапевтический журнал. 2026;(4):30-38.

Прочитано: 173 раза

Резюме

Нейрокогнитивные нарушения у пациентов с ВИЧ-инфекцией.

Дата публикации: 24.04.2026

Литература / References
  1. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986;19(6):517-524. https://doi.org/10.1002/ana.410190602
  2. May MT, Gompels M, Delpech V, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014;28(8):1193-1202. https://doi.org/10.1097/QAD.0000000000000243
  3. Heaton RK, Grant I, Butters N, et al. The HNRC500 – neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1(3):231-251. https://doi.org/10.1017/s1355617700000230
  4. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ; National HIV Surveillance Committee. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 2003;17(10):1539-1545. https://doi.org/10.1097/00002030-200307040-00015
  5. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087-2096. https://doi.org/10.1212/WNL.0b013e318200d727
  6. Maschke M, Kastrup O, Esser S, Ross B, Hengge U, Hufnagel A. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry. 2000;69(3):376-380. https://doi.org/10.1136/jnnp.69.3.376
  7. Wang Y, Liu M, Lu Q, et al. Global prevalence and burden of HIV-associated neurocognitive disorder: A meta-analysis. Neurology. 2020;95(19):e2610–e2621. https://doi.org/10.1212/WNL.0000000000010752
  8. Francesco D, Underwood J, Post FA, et al. Defining cognitive impairment in people-living-with-HIV: the POPPY study. BMC Infect Dis. 2016;16(1):617. https://doi.org/10.1186/s12879-016-1970-8
  9. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24(9):1243-1250. https://doi.org/10.1097/QAD.0b013e3283354a7b
  10. Gao C, Meng J, Xiao X, Wang M, Williams AB, Wang H. Antiretroviral therapy improves neurocognitive impairment in people living with HIV? A meta-analysis. Int J Nurs Sci. 2020;7(2):238-247. https://doi.org/10.1016/j.ijnss.2020.03.007
  11. Letendre SL, Chen H, McKhann A, et al. Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency Virus. Clin Infect Dis. 2023;77(6):866-874. https://doi.org/10.1093/cid/ciad265
  12. Qu Y, Weinstein A, Wang Z, et al. Legacy effect on neuropsychological function in HIV-infected men on combination antiretroviral therapy. AIDS. 2022;36(1):19-2. https://doi.org/10.1097/QAD.0000000000003071
  13. Milic J, Calza S, Lazzarini L, et al. Prevalence and risk factors of cognitive frailty in people with HIV. AIDS. 2026;40(2):133-142. https://doi.org/10.1097/QAD.0000000000004352
  14. Rubin LH, Neijna AG, Shi Q, et al. Degree of Polypharmacy and Cognitive Function in Older Women with HIV. AIDS Res Hum Retroviruses. 2022;38(7):571-579. https://doi.org/10.1089/AID.2021.0231
  15. Saloner R, Sun-Suslow N, Morgan EE, et al. Plasma biomarkers of vascular dysfunction uniquely relate to a vascular-risk profile of neurocognitive deficits in virally-suppressed adults with HIV. Brain Behav Immun Health. 2022;26:100560. https://doi.org/10.1016/j.bbih.2022.100560
  16. Ale BM, Amahowe F, Nganda MM, et al. Global burden of active smoking among people living with HIV on antiretroviral therapy: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10(1):12. https://doi.org/10.1186/s40249-021-00799-3
  17. Asfar T, Perez A, Shipman P, et al. National Estimates of Prevalence, Time-Trend, and Correlates of Smoking in US People Living with HIV (NHANES1999-2016). Nicotine Tob Res. 2021;23(8):1308-1317. https://doi.org/10.1093/ntr/ntaa277
  18. Monnig MA, Kahler CW, Lee H, et al. Effects of smoking and alcohol use on neurocognitive functioning in heavy drinking, HIV-positive men who have sex with men. AIDS Care. 2016;28(3):300-305. https://doi.org/10.1080/09540121.2015.1093595
  19. Letendre S, Bharti A, Perez-Valero I, et al. Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy. Clin Infect Dis. 2018;67(5):770-777. https://doi.org/10.1093/cid/ciy170
  20. Fitting S, Xu R, Bull C, et al. Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol. 2010;177(3):1397-1410. https://doi.org/10.2353/ajpath.2010.090945
  21. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789-1799. https://doi.org/10.1212/01.WNL.0000287431.88658.8b
  22. Gisslén M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis. 2011;11:356. https://doi.org/10.1186/1471-2334-11-356
  23. Meyer AC, Boscardin WJ, Kwasa JK, Price RW. Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-associated neurocognitive disorders? Impact of false-positive rates on prevalence and power. Neuroepidemiology. 2013;41(3-4):208-216. https://doi.org/10.1159/000354629
  24. Nightingale S, Dreyer AJ, Saylor D, Gisslén M, Winston A, Joska JA. Moving on From HAND: Why We Need New Criteria for Cognitive Impairment in Persons Living With Human Immunodeficiency Virus and a Proposed Way Forward. Clin Infect Dis. 2021;73(6):1113-1118. https://doi.org/10.1093/cid/ciab366
  25. Underwood J, De Francesco D, Leech R, Sabin CA, Winston A; Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study. Medicalising normality? Using a simulated dataset to assess the performance of different diagnostic criteria of HIV-associated cognitive impairment. PLoS One. 2018;13(4):e0194760. https://doi.org/10.1371/journal.pone.0194760
  26. Nightingale S, Ances B, Cinque P, et al. Cognitive impairment in people living with HIV: consensus recommendations for a new approach. Nat Rev Neurol. 2023;19(7):424-433. https://doi.org/10.1038/s41582-023-00813-2
  27. Трофимова Т. Н., Катаева Г. В., Громова Е. А. и др. ВИЧ-ассоциированные нейрокогнитивные нарушения: диагностика, выявление причин и эффективность терапии. ВИЧ-инфекция и иммуносупрессии. 2018;10(4):7-24.
  28. Haddow LJ, Floyd S, Copas A, Gilson RJ. A systematic review of the screening accuracy of the HIV Dementia Scale and International HIV Dementia Scale. PLoS One. 2013 Apr 16;8(4):e61826. https://doi.org/10.1371/journal.pone.0061826
  29. Robbins RN, Joska JA, Thomas KG, et al. Exploring the utility of the Montreal Cognitive Assessment to detect HIV-associated neurocognitive disorder: the challenge and need for culturally valid screening tests in South Africa. Clin Neuropsychol. 2013;27(3):437-454. https://doi.org/10.1080/13854046.2012.759627
  30. Renborg L, Yilmaz A, Nilsson S, Zetterberg H, Blennow K, Gisslén M. Rapid decline of cerebrospinal fluid biomarkers of axonal injury and neuroinflammation after initiation of antiretroviral therapy in HIV. J Neurovirol. 2025;31(6):574-584. https://doi.org/10.1007/s13365-025-01287-2
  31. Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS. 2013;27(9):1387-1395. https://doi.org/10.1097/QAD.0b013e32836010bd
  32. Ma J, Yang X, Xu F, Li H. Application of Diffusion Tensor Imaging (DTI) in the Diagnosis of HIV-Associated Neurocognitive Disorder (HAND): A Meta-Analysis and a System Review. Front Neurol. 2022;13:898191. https://doi.org/10.3389/fneur.2022.898191
  33. Chaganti J, Brew BJ. MR spectroscopy in HIV associated neurocognitive disorder in the era of cART: a review. AIDS Res Ther. 2021;18(1):65. https://doi.org/10.1186/s12981-021-00388-2
  34. Vera JH, Guo Q, Cole JH, et al. Neuroinflammation in treated HIV-positive individuals: A TSPO PET study. Neurology. 2016;86(15):1425-1432. https://doi.org/10.1212/WNL.0000000000002485
  35. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis. 2006;194(12):1686-1696. https://doi.org/10.1086/508750
  36. Johnson TP, Nath A. New insights into immune reconstitution inflammatory syndrome of the central nervous system. Curr Opin HIV AIDS. 2014;9(6):572-578. https://doi.org/10.1097/COH.0000000000000107
  37. Ellis RJ, Marquine MJ, Kaul M, Fields JA, Schlachetzki JCM. Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management. Nat Rev Neurol. 2023;19(11):668-687. https://doi.org/10.1038/s41582-023-00879-y
  38. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65-70. https://doi.org/10.1001/archneurol.2007.31
  39. Etherton MR, Lyons JL, Ard KL. HIV-associated Neurocognitive Disorders and Antiretroviral Therapy: Current Concepts and Controversies. Curr Infect Dis Rep. 2015;17(6):485. https://doi.org/10.1007/s11908-015-0485-6
  40. Zhao Y, Navia BA, Marra CM, et al. Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials. 2010;11(1):59-67. https://doi.org/10.1310/hct1101-59
  41. Schifitto G, Navia BA, Yiannoutsos CT, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007;21(14):1877-1886. https://doi.org/10.1097/QAD.0b013e32813384e8
  42. Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology. 2007;69(13):1314-1321. https://doi.org/10.1212/01.wnl.0000268487.78753.0f
  43. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology. 1998;50(3):645-651. https://doi.org/10.1212/wnl.50.3.645
  44. Nakasujja N, Miyahara S, Evans S, et al. Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology. 2013;80(2):196-202. https://doi.org/10.1212/WNL.0b013e31827b9121
  45. Schifitto G, Zhong J, Gill D, et al. Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol. 2009;15(2):176-186. https://doi.org/10.1080/13550280902758973
  46. Letendre SL, Woods SP, Ellis RJ, et al. Lithium improves HIV-associated neurocognitive impairment. AIDS. 2006;20(14):1885-1888. https://doi.org/10.1097/01.aids.0000244208.49123.1b
  47. Schifitto G, Peterson DR, Zhong J, et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology. 2006;66(6):919-921. https://doi.org/10.1212/01.wnl.0000204294.28189.03
  48. Sacktor N, Skolasky RL, Moxley R, et al. Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial. J Neurovirol. 2018;24(1):16-27. https://doi.org/10.1007/s13365-017-0587-z
  49. Ances BM, Anderson AM, Letendre SL. CROI 2021: Neurologic Complications of HIV-1 Infection or Covid-19. Top Antivir Med. 2021;29(2):334-343.
  50. Craft S, Raman R, Chow TW, et al. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA Neurol. 2020;77(9):1099-1109. https://doi.org/10.1001/jamaneurol.2020.1840
  51. McElhiney M, Rabkin J, Van Gorp W, Rabkin R. Modafinil effects on cognitive function in HIV+ patients treated for fatigue: a placebo controlled study. J Clin Exp Neuropsychol. 2010;32(5):474-480. https://doi.org/10.1080/13803390903201769
  52. Clifford DB, McArthur JC, Schifitto G, et al. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology. 2002;59(10):1568-1573. https://doi.org/10.1212/01.wnl.0000034177.47015.da
  53. Boivin MJ, Nakasujja N, Sikorskii A, Opoka RO, Giordani B. A Randomized Controlled Trial to Evaluate if Computerized Cognitive Rehabilitation Improves Neurocognition in Ugandan Children with HIV. AIDS Res Hum Retroviruses. 2016;32(8):743-755. https://doi.org/10.1089/AID.2016.0026
  54. Vance DE, Fazeli PL, Azuero A, Wadley VG, Raper JL, Ball KK. Can Individualized-Targeted Computerized Cognitive Training Benefit Adults with HIV-Associated Neurocognitive Disorder? The Training on Purpose Study (TOPS). AIDS Behav. 2021;25(12):3898-3908. https://doi.org/10.1007/s10461-021-03230-y
  55. Ezeamama AE, Sikorskii A, Sankar PR, et al. Computerized Cognitive Rehabilitation Training for Ugandan Seniors Living with HIV: A Validation Study. J Clin Med. 2020;9(7):2137. https://doi.org/10.3390/jcm9072137
  56. Vance DE, Fazeli PL, Azuero A, et al. A 2-year longitudinal randomized controlled trial examining the transfer of speed of processing training to secondary cognitive domains in middle-aged and older adults with HIV-associated neurocognitive disorder: Results of the think fast study. Clin Neuropsychol. 2024;38(2):471-492. https://doi.org/10.1080/13854046.2023.2212867
  57. Mayo NE, Levine B, Brouillette MJ, Bélanger D, Fellows LK. Efficacy potential of Goal Management Training to improve cognitive function in older people living with HIV. Contemp Clin Trials Commun. 2022;30:101023. https://doi.org/10.1016/j.conctc.2022.101023
  58. Nweke M, Nombeko M, Govender N, Akinpelu A, Ukwuoma M, Ogunniyi A. Aerobic exercise for HIV-associated neurocognitive disorders in individuals on antiretroviral therapy: A randomised controlled trial. Clin Rehabil. 2022;36(12):1601-1612. https://doi.org/10.1177/02692155221114587
  59. Henry BL, Moore DJ. Preliminary Findings Describing Participant Experience With iSTEP, an mHealth Intervention to Increase Physical Activity and Improve Neurocognitive Function in People Living With HIV. J Assoc Nurses AIDS Care. 2016;27(4):495-511. https://doi.org/10.1016/j.jana.2016.01.001
  60. Morrison SA, Fazeli PL, Gower B, et al. Cognitive Effects of a Ketogenic Diet on Neurocognitive Impairment in Adults Aging With HIV: A Pilot Study. J Assoc Nurses AIDS Care. 2020;31(3):312-324. https://doi.org/10.1097/JNC.0000000000000110
  61. Ceccarelli G, Brenchley JM, Cavallari EN, et al. Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals. Nutrients. 2017;9(11):1269. https://doi.org/10.3390/nu9111269
  62. Ownby RL, Kim J. Computer-Delivered Cognitive Training and Transcranial Direct Current Stimulation in Patients With HIV-Associated Neurocognitive Disorder: A Randomized Trial. Front Aging Neurosci. 2021;13:766311. https://doi.org/10.3389/fnagi.2021.766311
slide-cover
slide-cover
slide-cover
slide-cover
Издательство «Медиа Сфера»
РекламаДоставка/ОплатаО насКонтактыОбучение для редакцийПолитика конфиденциальностиПолитика обработки персональных данныхПубличная оферта на реализацию издательской продукции
ЖурналыПодпискаАрхивКнигиПроекты
  • RuStore

© 1998-2026

  • Телефоны издательства:

  • +7 (495) 482-41-18
  • +7 (495) 482-43-29

  • Прямой телефон отдела подписки
    (только по вопросам заказов и доставки журналов)

  • +7 (800) 250-18-12

  • пн-пт с 10:00 до 18:00

  • Telegram
  • VK
info@mediasphera.ru

  • Почтовый адрес:

  • Издательство «Медиа Сфера»,
    а/я 54, Москва, Россия, 127238

  • RuStore

© 1998-2026